IPT Autumn 2026 is live! Explore how CARBOGEN AMCIS are making pharmaceutical manufacturing more #sustainable, #labintheloop architecture with Thermo Fisher Scientific, and #antibodydesign with Nuclera, plus lots more
Read here: https://t.co/fF6vBroNF8
#pharmatech
The testing blind spot
Could digital integration and smarter workflows transform the #NHS's pre-analytical process and improve #patientsafety?
✏️ Kevin Moore, Salutare
Read here: https://t.co/FkZe1UXJw2
From concept to clinic – partnering to scale up cell and gene therapies
How can the industry bridge the gap between cell and gene therapy innovation and reliable large-scale manufacturing?
✏️Nitin Kulkarni and Rama Shivakumar
@MaxCyte_info
Read here: https://t.co/cDKeAp0wKI
Resilience in #pharmaceuticalmanufacturing: what connected operations now require
Pharmaceutical manufacturers are rethinking operational resilience.
✏️Owen Bonner
@honeywell
Read here: https://t.co/VYJ7UyNJBU
From variability to predictability: redefining visual inspection in high-mix #pharmamanufacturing
In high-mix environments, inspection systems must first be flexible – everything else builds on that foundation
✏️Robert Kibele
@KoerberPharma
Read here: https://t.co/BUSj8Bw8SJ
The #manufacturing executive’s new shield: closing the records liability gap
As regulators increasingly focus on individual accountability, can manufacturing leaders afford to treat data governance as a back-office function?
✏️Trevor Vick, UMIP
Read here: https://t.co/LqKOCrPyvO
A new kind of blockbuster: could autonomous manufacturing transform #pharma?
Will the next generation of #blockbustertherapies be won by science alone or by the speed of manufacturing execution?
✏️Dave Tudor at DTG
Read here: https://t.co/T3DYxLognl
Fit-for-purpose measurement in #drugdevelopment: aligning analytics with decision-making across workflows
✏️Ruizhi Wang and Paolo Romele
@AbselionX
Read here: https://t.co/NiUdkMLcVB
Cell-based workflows: the missing data layer in AI-enabled #drugdiscovery
Can #artificialintelligence truly transform drug discovery without equally transforming the biology and data that underpin it?
✏️Jeroen Verheyen
@Semarion_Ltd
Read here: https://t.co/vqi9L8skQk
Silence and noise: twin threats to scientific resilience in #biopharma R&D
As workforce turnover reshapes the industry, how can organisations preserve the knowledge that drives scientific progress?
✏️Sophie Lutter at Lab Thread
Read here: https://t.co/1vEWBBhMFO
De-risking gene therapy development through efficient stress testing of #viralvectors
Could next-generation #analyticaltechnologies unlock faster, more informative stress testing for viral vectors?
✏️Jacintha Victoria at Refeyn
Read here: https://t.co/SWhoV7hQ9v
How human tissue models could transform preclinical #drugdevelopment#Animaltesting in #drugdevelopment is facing growing pressure as scientists and regulators adopt more human-relevant alternatives.
✏️Mark Lewis at Myomaker Bio
Read here: https://t.co/vSZJaBLynU
From sample to insight: how #spatialbiology is transforming cancer prognosis and clinical research
✏️Sherry Derakhshani
@zeiss_micro
Read here: https://t.co/qLhnSzMcKV
IPT Summer 2026 is now live! Read on for fascinating articles about spatial biology from @zeiss_micro, manufacturing in life sciences from @honeywell Life Sciences, and iPSC-dervied models from FUJIFILM @CellDynamics, plus lots more.
Read here: https://t.co/gXDHz8vR9D
#pharmtech